Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511810 · ClinicalTrials.gov registry record · Phase 2
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00511810 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 20 participants.
The verdict
NCT00511810, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD. The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently increase prefrontal cortical functional activation during sustained attention and increase regional biochemical indices of cortical metabolism and integrity concentrations in association with reductions in depressive symptoms.
Interventions
- DRUG High Dose Fish Oil
- DRUG Low Dose Fish Oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511810
The ClinicalTrials.gov registry entry for NCT00511810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which High Dose Fish Oil is the first listed.
NCT00511810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511810 about?
NCT00511810 is a clinical study titled "Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder". The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD. The primary prediction was that LCn-3 fatty acid supplementation would dose-de...
What is the current status of trial NCT00511810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-08. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00511810?
The interventions under investigation include: High Dose Fish Oil (DRUG), Low Dose Fish Oil (DRUG).
Who is sponsoring clinical trial NCT00511810?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.